# Bristol Myers multiple myeloma drug improves survival by 50% in late-stage study.

*biotech · news · 2026-05-29 · Seeking Alpha*

## Key points

- Bristol Myers' mezigdomide improved cancer-free survival by over 50% in a late-stage myeloma trial.
- Mezigdomide was tested as part of a combination regimen for multiple myeloma.
- This result comes from a late-stage, or Phase 3, clinical trial.
- Mezigdomide is an antitumor candidate specifically developed for multiple myeloma treatment.

Bristol Myers multiple myeloma drug improves survival by 50% in late-stage study May 29, 2026, 9:09 AM ETBristol-Myers Squibb Company (BMY) StockKDBy : Dulan Lokuwithana, SA News Editor Comments (2) Bristol Myers Squibb (BMY) announced on Friday that its antitumor candidate mezigdomide, as part of a combination regimen, improved cancer-free survival by more than 50% in a late-stage trial for multiple myeloma, a type of blood cancer. Citing data from Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** Bristol Myers Squibb

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4598379-bristol-myers-posts-phase-3-win-multiple-myeloma-drug)

---

Canonical: https://newsio.io/n/96dfaf68-11b4-4c4d-946a-5096b7603b8f/bristol-myers-multiple-myeloma-drug-improves-survival-by-50-in-late-stage-study
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works